MYMustafa Kemal Yeniay

Mustafa Kemal Yeniay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustafa Kemal Yeniay has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma

    by Mustafa Kemal Yeniay, Özlem Anlaş, Feyza Altunbaş Yalabık, Zehra Narlı Özdemir, Oktay Bilgir

    Aims: To evaluate the association of fluorescence in situ hybridization (FISH)-defined cytogenetic risk and baseline positron emission tomography/computed tomography (PET/CT) findings with early treatment response and early disease progression in patients with newly diagnosed multiple myeloma (MM). Methods: Seventy patients with newly diagnosed MM were included in this retrospective study. Clinical characteristics, International Staging System (ISS) and Revised ISS (R-ISS) stage, lactate dehydrogenase (LDH) level, FISH-defined cytogenetic risk, and baseline PET/CT parameters, including the number of focal lesions, maximum standardized uptake value (SUV max), extramedullary disease, bone marrow involvement, and metabolic risk group, were recorded. Treatment responses after the second and fourth cycles were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory associations with PFS were assessed using Cox proportional hazards regression. Results: According to baseline PET/CT, 81.4% of patients were classified as having a metabolically high-risk disease. Compared with the metabolically low-risk group, patients in the metabolically high-risk group achieved significantly higher rates of very good partial response (VGPR) after the second cycle (49.1% vs. 15.4%, p=0.032) and ≥VGPR after the fourth cycle (64.9% vs. 23.1%, p=0.011). However, progression rates did not differ significantly between the two groups (p=0.675). Although response rates and progression frequency were numerically higher in the FISH high-risk group, these differences did not reach statistical significance. Kaplan–Meier analysis demonstrated longer PFS in female patients (p=0.001); ≥VGPR after the fourth cycle was not significantly associated with PFS (p=0.116). In the multivariable Cox model (13 PFS events), female sex remained significantly associated with PFS (HR=0.067, 95% CI 0.008–0.569, p=0.013), although the estimate was unstable because of the very limited number of events. The 1-year PFS and OS rates were 86% and 92%, respectively. Conclusion: In this exploratory cohort, the study-specific PET/CT metabolic risk classification was associated with deeper early treatment responses but not with short-term disease progression. FISH-defined cytogenetic risk was not significantly associated with early response or progression. Given the short follow-up duration, limited number of events, and lack of external validation of the metabolic risk classification, these findings should be considered preliminary and do not establish the independent prognostic value of PET/CT or FISH-defined risk.

  • 2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group

    by Meral Beksac, Metban Mastanzade, Basak Bostankolu Degirmenci, Beyza Oluk, Bugra Saglam, Dilek Ozden Ozluk, Esra Cengiz, Fadime Nurcan Alhan, Hatice Zeynep Dikici, Kubra Yel Uygun, et al.

  • Open Access

    Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye

    by Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan, Nevin Alayvaz Aslan, Süleyman Utku Uzun, Kayıhan Kara, Utku Iltar, Orhan Kemal Yücel, Ünal Ataş, Selin Arslan Kirezli, et al.

    Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye. Methods: This multicenter retrospective study included 87 patients with relapsed/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes. Results: At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade ≥ 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade ≥ 3 events occurred. Grade ≥ 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively. Conclusions: Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.

  • Spontaneous Intramuscular Hematoma due to Subcutaneous Enoxaparın

    by Ahmet Gürdal, Mustafa Kemal Yeniay, Şükrü Çetin, Kadriye Kılıçkesmez